Equities analysts forecast that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post $5.77 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $6.48 million and the lowest estimate coming in at $5.20 million. Aclaris Therapeutics reported sales of $3.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 56.8%. The business is expected to issue its next quarterly earnings results after the market closes on Thursday, August 8th.
On average, analysts expect that Aclaris Therapeutics will report full year sales of $23.16 million for the current fiscal year, with estimates ranging from $20.80 million to $25.81 million. For the next year, analysts anticipate that the business will report sales of $36.47 million, with estimates ranging from $19.90 million to $53.94 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). The company had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%.
A number of analysts recently weighed in on ACRS shares. Leerink Swann downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. ValuEngine upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Cantor Fitzgerald decreased their price objective on Aclaris Therapeutics from $50.00 to $24.00 and set an “overweight” rating for the company in a report on Wednesday, June 12th. Finally, Svb Leerink downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 27th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Aclaris Therapeutics has an average rating of “Hold” and an average target price of $19.69.
NASDAQ ACRS traded down $0.10 on Monday, reaching $1.11. The company had a trading volume of 1,517,602 shares, compared to its average volume of 664,602. Aclaris Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $18.98. The business has a 50 day moving average price of $2.73. The company has a quick ratio of 4.30, a current ratio of 4.33 and a debt-to-equity ratio of 0.16.
In other Aclaris Therapeutics news, major shareholder James E. Flynn sold 339,537 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $4.62, for a total transaction of $1,568,660.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn sold 454,261 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $4.59, for a total value of $2,085,057.99. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,107,983 shares of company stock valued at $9,303,479. Company insiders own 14.80% of the company’s stock.
A number of institutional investors have recently modified their holdings of ACRS. BlackRock Inc. grew its holdings in Aclaris Therapeutics by 43.8% during the 4th quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock worth $26,759,000 after acquiring an additional 1,103,423 shares during the period. Dimensional Fund Advisors LP grew its holdings in Aclaris Therapeutics by 105.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 489,516 shares of the biotechnology company’s stock worth $3,618,000 after acquiring an additional 250,963 shares during the period. Rice Hall James & Associates LLC grew its holdings in Aclaris Therapeutics by 29.2% during the 1st quarter. Rice Hall James & Associates LLC now owns 699,307 shares of the biotechnology company’s stock worth $4,189,000 after acquiring an additional 158,056 shares during the period. Tibra Equities Europe Ltd acquired a new stake in Aclaris Therapeutics during the 1st quarter worth about $662,000. Finally, Geode Capital Management LLC grew its holdings in Aclaris Therapeutics by 38.4% during the 4th quarter. Geode Capital Management LLC now owns 380,007 shares of the biotechnology company’s stock worth $2,808,000 after acquiring an additional 105,361 shares during the period. Hedge funds and other institutional investors own 91.33% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Featured Article: Stock Symbols and CUSIP Explained
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.